Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

New report reveals striking variation in cancer burden within AANHPI population

A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.

18 Jan 2016

UTHealth receives nearly $5.7 million from CPRIT for cancer research

The Cancer Prevention & Research Institute of Texas has awarded nearly $5.7 million in grants to The University of Texas Health Science Center at Houston School of Public Health. The grants will fund projects that train innovative cancer researchers, increase breast and cervical cancer screening among Hispanics and raise awareness about the human papillomavirus (HPV) vaccine.

22 Dec 2015

CMFT adopts ZedScan system to improve cervical cancer care

DP Medical Systems Ltd has secured a deal with Central Manchester University Hospitals NHS Foundation Trust (CMFT) to adopt ZedScan™ as part of its cervical cancer care pathway.

From Zilico 21 Dec 2015

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen Pharmaceuticals, Inc. announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.

20 Dec 2015

Discovery could pave way for targeted therapies to treat penile cancer

Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments.

15 Dec 2015

New combination approach to eradicate established tumors

A laboratory study conducted at Leiden University Medical Center in the Netherlands has found that immunotherapy can be efficiently combined with photodynamic therapy (PDT) to eradicate established tumors. The approach results in strong local tumor destruction and a robust systemic immune response against the disease.

27 Nov 2015

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.

10 Nov 2015

Research sheds new light on the fight against tonsil cancer

Researchers at Simon Fraser University and the BC Cancer Agency have developed a groundbreaking method to identify and separate stem cells that reside in the tonsils. Their research, which sheds new light on the fight against oral cancer, is published today in the journal Stem Cell Reports.

3 Nov 2015

Around 20% of ethnic school girls not vaccinated against HPV

Around 20 per cent of girls from ethnic minority backgrounds are not being vaccinated against the Human Papilloma Virus (HPV) because they feel they don't need to have it, according to a Cancer Research UK survey presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool*.

2 Nov 2015

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Outreach program increases completion of HPV vaccination series by teens in safety-net settings

A joint study by UT Southwestern Medical Center and Parkland Health & Hospital System investigators found that a multicomponent outreach program increased completion of the three-dose human papillomavirus (HPV) vaccination series that reduces the risk of cervical cancer caused by the virus.

19 Oct 2015

Study reveals high rates of preventable cancers in Indigenous peoples of high-income countries

Research published in The Lancet Oncology, led by the International Agency for Research on Cancer (IARC) on the scale and profile of cancer in indigenous peoples of the USA, Canada, Australia and New Zealand has revealed high rates of often preventable cancers including lung and cervical cancer, emphasising the need for targeted prevention strategies in these populations.

16 Oct 2015

Prevention of cervical cancer in Latin America

The latest Special Issue from ecancermedicalscience collects four new research articles on the topic of cervical cancer prevention in Latin America.

12 Oct 2015

New smartphone-based device can reliably perform molecular diagnoses at low cost

NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.

6 Oct 2015

NeoGenomics introduces new NeoSITE Cervical FISH assay

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its comprehensive FISH (Fluorescence In Situ Hybridization) testing menu to include a new NeoSITE Cervical assay to provide additional diagnostic information on abnormal Pap smears.

23 Sep 2015

Genetically engineered vaccine eradicates precancerous cervical lesions

Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV.

18 Sep 2015

Cells expressing faulty CFTR channel to TNF-α can 'fix' cystic fibrosis cells

Scientific experiments examining what happens to the faulty channel protein that causes cystic fibrosis during inflammation have yielded unexpected and exciting results. The study, conducted by Sara Bitam and her colleagues at INSERM in France, has just passed peer review on open science publishing platform F1000Research.

3 Sep 2015

Meridian Health Plan has second highest rate of HPV vaccinations in U.S. for female adolescents

Meridian Health Plan of Illinois has the second highest rate of human papillomavirus (HPV) vaccinations for female adolescents among all health plans in the country reporting HEDIS data to the National Committee for Quality Assurance.

14 Aug 2015

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student.